中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

108 records (took 0.027 seconds)

    TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
    5.
    发明授权
    TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof 有权

    公开(公告)号：US11440949B2

    公开(公告)日：2022-09-13

    申请号：US16340040

    申请日：2017-10-05

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako ,  Roselyne Castonguay

    IPC: C07K14/71 ,  A61K38/00

    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK.6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.

    ACTRII-BINDING PROTEINS AND USES THEREOF
    6.
    发明申请
    ACTRII-BINDING PROTEINS AND USES THEREOF 有权

    公开(公告)号：US20220242956A1

    公开(公告)日：2022-08-04

    申请号：US17615474

    申请日：2020-05-29

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Jonathan Belk ,  Asya Grinberg ,  Dianne Sako ,  Roselyne Castonguay

    IPC: C07K16/28 ,  C12N15/63

    Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

    SINGLE-ARM CO-RECEPTOR FUSION PROTEINS AND USES THEREOF
    9.
    发明申请
    SINGLE-ARM CO-RECEPTOR FUSION PROTEINS AND USES THEREOF 有权

    公开(公告)号：US20210107959A1

    公开(公告)日：2021-04-15

    申请号：US16959466

    申请日：2019-01-02

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako

    IPC: C07K14/495

    Abstract: In certain aspects, the disclosure provides single-arm heteromeric polypeptide complexes comprising an extracellular domain of a co-receptor of the TGF-beta superfamily. In some embodiments, the disclosure provides single-arm polypeptide complexes comprising an extracellular domain of a co-receptor selected from: endoglin, betaglycan, Cripto-1, Cryptic, Cryptic family protein 1B, Crim 1, Crim2, BAMBI, BMPER, RGM-A, RGM-B, MuSK, and hemojuvelin. Optionally the complex is a heterodimer. In certain aspects, such polypeptide complexes may be used for the treatment or prevention of various TGF-beta associated conditions, including without limitation diseases and disorders associated with, for example, cancer, muscle, bone, fat, red blood cells, metabolism, fibrosis and other tissues that are affected by one or more ligands of the TGF-beta superfamily.

    VARIANT ACTRIIB PROTEINS AND USES THEREOF
    10.
    发明申请
    VARIANT ACTRIIB PROTEINS AND USES THEREOF 审中-公开

    公开(公告)号：US20200055919A1

    公开(公告)日：2020-02-20

    申请号：US16340048

    申请日：2017-10-05

    Applicant: Acceleron Pharma Inc.

    Inventor： Ravindra Kumar ,  Asya Grinberg ,  Erik M. Vogan

    IPC: C07K14/71 ,  A61P21/00

    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

Patent Agency Ranking